275 related articles for article (PubMed ID: 16690359)
1. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G
Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.
DeWeese TL; van der Poel H; Li S; Mikhak B; Drew R; Goemann M; Hamper U; DeJong R; Detorie N; Rodriguez R; Haulk T; DeMarzo AM; Piantadosi S; Yu DC; Chen Y; Henderson DR; Carducci MA; Nelson WG; Simons JW
Cancer Res; 2001 Oct; 61(20):7464-72. PubMed ID: 11606381
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC
Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
Freytag SO; Khil M; Stricker H; Peabody J; Menon M; DePeralta-Venturina M; Nafziger D; Pegg J; Paielli D; Brown S; Barton K; Lu M; Aguilar-Cordova E; Kim JH
Cancer Res; 2002 Sep; 62(17):4968-76. PubMed ID: 12208748
[TBL] [Abstract][Full Text] [Related]
5. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Nemunaitis J; Cunningham C; Buchanan A; Blackburn A; Edelman G; Maples P; Netto G; Tong A; Randlev B; Olson S; Kirn D
Gene Ther; 2001 May; 8(10):746-59. PubMed ID: 11420638
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.
Trudel S; Trachtenberg J; Toi A; Sweet J; Li ZH; Jewett M; Tshilias J; Zhuang LH; Hitt M; Wan Y; Gauldie J; Graham FL; Dancey J; Stewart AK
Cancer Gene Ther; 2003 Oct; 10(10):755-63. PubMed ID: 14502228
[TBL] [Abstract][Full Text] [Related]
7. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
8. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
9. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
Reid T; Galanis E; Abbruzzese J; Sze D; Wein LM; Andrews J; Randlev B; Heise C; Uprichard M; Hatfield M; Rome L; Rubin J; Kirn D
Cancer Res; 2002 Nov; 62(21):6070-9. PubMed ID: 12414631
[TBL] [Abstract][Full Text] [Related]
11. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
Rademaker-Lakhai JM; Horenblas S; Meinhardt W; Stokvis E; de Reijke TM; Jimeno JM; Lopez-Lazaro L; Lopez Martin JA; Beijnen JH; Schellens JH
Clin Cancer Res; 2005 Mar; 11(5):1854-62. PubMed ID: 15756010
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
15. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.
Xu F; Li S; Li XL; Guo Y; Zou BY; Xu R; Liao H; Zhao HY; Zhang Y; Guan ZZ; Zhang L
Cancer Gene Ther; 2009 Sep; 16(9):723-30. PubMed ID: 19363470
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Eder JP; Kantoff PW; Roper K; Xu GX; Bubley GJ; Boyden J; Gritz L; Mazzara G; Oh WK; Arlen P; Tsang KY; Panicali D; Schlom J; Kufe DW
Clin Cancer Res; 2000 May; 6(5):1632-8. PubMed ID: 10815880
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.
Liu G; Oettel K; Ripple G; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Marnocha R; Bruskewitz R; Mazess R; Bishop C; Bhattacharya A; Bailey H; Wilding G
Clin Cancer Res; 2002 Sep; 8(9):2820-7. PubMed ID: 12231522
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
